Polymorphic form X of nilotinib dihydrochloride hydrate
US10301282B2 · kind B2 · utility
6Cited by
2References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 21, 2016 |
| Grant date | May 28, 2019 |
| Priority date | — |
| Expiry date | Mar 21, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07B2200/13
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present invention relates to a novel polymorph of nilotinib hydrochloride (Form X), to processes for its preparation, to pharmaceutical compositions containing the same and to its use in medicine.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.